Hard to Treat Diseases, Incorporated Announces: Status of Colorado and Oklahoma Replevin Actions
DELRAY BEACH, FL -- (MARKET WIRE) -- 11/03/2005 -- Hard To Treat Diseases, Incorporated (HTTD) (OTC: HTDS) announces Colorado Judge grants HTTD's Motion to Intervene in Denver case, Denver testing entities file Motions to Dismiss case and Shinn Capital is unsuccessful in acquiring HTTD's Tubercin and testing results at yesterday's court hearing in Denver.
HTTD's assets include Tubercin and testing results from Denver and Oklahoma, resulting from agreements for testing entered into and paid for by HTTD. Shinn Capital has possessed a license agreement to market Tubercin for over five years and accomplished nothing: it has no Tubercin, no testing results and no credibility.
HTTD's CEO Colm King states, "If Shinn wants testing results, he should find a testing facility willing to perform work for him and expect to pay for results. HTTD is not willing to share its valuable results with misleading non-performers."
All motions and court documents will be posted on the Company's website at: www.htdsotc.com as soon as possible. Mr. King will also attend the Oklahoma replevin hearing scheduled for next Thursday, November 10. Shareholders will be informed on the outcome.
HTTD is moving forward on all fronts; securing rights to Tubercin, advancing our provisional patent for the treatment of viral infections and the assignment of various recycling patents to the Company.
Cautionary Note Regarding Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
CONTACT:
Colm J. King, CEO
Hard to Treat Diseases, Incorporated
(561) 278-7856
www.htdsotc.com
SOURCE: Hard to Treat Diseases Inc.
marketwire.com |
